{"product_id":"knee-surgery-vs-sham-surgery-for-degenerative-meniscus-tears-a-2-year-study-shows-no-advantage","title":"Knee Surgery vs. Sham Surgery for Degenerative Meniscus Tears: A 2-Year Study Shows No Advantage","description":"\u003cp\u003eThis 2-year follow-up study, called the FIDELITY trial (Finnish Degenerative Meniscal Lesion Study), compared arthroscopic partial meniscectomy (APM) — a common knee surgery that trims away a torn meniscus — against placebo (simulated) surgery in 146 adults aged 35–65 with degenerative medial meniscus tears and no knee osteoarthritis. The results showed no significant differences between the two groups in any measured outcome, including knee function, pain levels, patient satisfaction, or return to normal activities. Even patients with \"mechanical symptoms\" (like catching or locking) or unstable meniscus tears did not benefit more from real surgery than from placebo. These findings challenge the widespread belief that arthroscopic surgery is needed when conservative treatment fails.\u003c\/p\u003e\n\n\u003ch1\u003eKnee Surgery vs. Sham Surgery for Degenerative Meniscus Tears: A 2-Year Study Shows No Advantage\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-design\"\u003eStudy Design: How the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#participants\"\u003eWho Participated in the Study\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: Results After 24 Months\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#subgroup-analysis\"\u003eSubgroup Analysis: Do Certain Patients Benefit More?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What the Study Couldn't Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations: What Patients Should Consider\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn 146 adults aged 35–65 with degenerative meniscus tears and no significant arthritis, arthroscopic partial meniscectomy was no better than sham surgery at 2 years.\u003c\/li\u003e\n\u003cli\u003ePatients with mechanical symptoms like catching or locking and those with unstable tear patterns did not benefit more from real surgery than placebo.\u003c\/li\u003e\n\u003cli\u003eBoth groups improved markedly, suggesting natural healing, exercise, time, and placebo effects drive most improvement, not removal of torn cartilage.\u003c\/li\u003e\n\u003cli\u003eOne serious knee infection occurred in 70 real-surgery patients (1.4%); no serious event occurred in the placebo group.\u003c\/li\u003e\n\u003cli\u003eConservative treatment such as physical therapy and a home exercise program should be the first-line approach, with surgery reserved for careful discussion of risks and evidence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eArthroscopic partial meniscectomy (APM) is one of the most commonly performed orthopedic operations in the world. In this procedure, a surgeon inserts a small camera called an arthroscope into the knee joint and uses tiny instruments to remove the damaged portions of the meniscus — the C-shaped cartilage that acts as a shock absorber between the thigh bone (femur) and shin bone (tibia).\u003c\/p\u003e\n\n\u003cp\u003eThe use of this surgery increased steadily from the 1990s through the late 2010s. Most APM procedures are performed on middle-aged and older patients who have knee symptoms related to degenerative knee disease (age-related wear and tear of the joint).\u003c\/p\u003e\n\n\u003cp\u003eHowever, several recent meta-analyses (studies that combine results from multiple clinical trials) based on randomized controlled trials have failed to show that APM provides a benefit over conservative (non-surgical) treatment or placebo surgery for these patients. Conservative treatment typically includes physical therapy, pain medications, activity modification, and home exercise programs.\u003c\/p\u003e\n\n\u003cp\u003eAligned with this evidence, most medical guidelines and expert opinions now recommend against APM as the first-line treatment for patients with a degenerative meniscus tear. However, many guidelines still advocate surgery after a patient has failed a trial of conservative treatment. This recommendation rests on three foundations:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eGenerally favorable clinical experience with the surgery\u003c\/li\u003e\n  \u003cli\u003eSome before-and-after studies showing improvement in patients who undergo APM due to persistent symptoms despite conservative treatment\u003c\/li\u003e\n  \u003cli\u003eEvidence from three earlier randomized controlled trials in which about one-third of patients initially assigned to non-surgical treatment eventually \"crossed over\" to APM because their knee symptoms persisted or didn't improve enough\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn those earlier trials, participants who crossed over to surgery achieved similar outcomes to those who were initially assigned to surgery and those who responded well to conservative treatment alone. Some experts interpreted this as evidence that APM should be performed after failed conservative treatment. But the researchers of this current study point out an alternative explanation: because those trials were not blinded (patients knew whether they had surgery or not), patients who didn't receive surgery may have been disappointed and therefore requested surgery, while also feeling more satisfied with the outcome once they finally had the operation — a psychological effect that can mask the true value of the procedure itself.\u003c\/p\u003e\n\n\u003cp\u003eBeyond patients who fail conservative treatment, other groups commonly believed to benefit from APM include those with so-called \"mechanical symptoms\" (such as catching, clicking, or locking of the knee) and those with \"unstable\" meniscus tears (tears with certain shapes — longitudinal, bucket handle, or flap patterns — that are thought to cause more mechanical problems).\u003c\/p\u003e\n\n\u003ch2 id=\"study-design\"\u003eStudy Design: How the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis study was a multicentre, randomized, participant-blinded and outcome assessor-blinded, placebo-surgery controlled efficacy trial. In plain terms:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMulticentre:\u003c\/strong\u003e The study took place at five orthopedic centers in Finland\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRandomized:\u003c\/strong\u003e Patients were assigned by chance to one of two groups\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eParticipant-blinded:\u003c\/strong\u003e Patients did not know whether they received the real surgery or the sham (placebo) procedure\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOutcome assessor-blinded:\u003c\/strong\u003e The doctors evaluating results did not know which treatment patients received\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlacebo-surgery controlled:\u003c\/strong\u003e One group received simulated surgery to test whether the real operation offers anything beyond the placebo effect\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe study was conducted from December 2007 through March 2014. All participants were aged 35 to 65 years and had knee symptoms lasting more than 3 months that were consistent with a degenerative medial meniscus tear. Importantly, patients had no clinical or radiographic signs of knee osteoarthritis (Kellgren-Lawrence grade 0 or 1, meaning no or only minor degenerative changes on X-ray).\u003c\/p\u003e\n\n\u003cp\u003eAll patients had a suspected meniscus tear based on symptoms and clinical tests, and the tear was later confirmed on both magnetic resonance imaging (MRI) and during knee arthroscopy itself. Patients with symptoms caused by an obvious trauma (like falling from a chair, stairs, or bicycle, or slipping on ice) and those with a recent history of a locked knee were excluded from the trial. However, patients with sudden symptoms related to voluntary muscle activities (such as kneeling, bending, or kicking) or a minor twist of the knee were included.\u003c\/p\u003e\n\n\u003cp\u003eBefore the procedure, all participants were told that if they did not get adequate relief of symptoms, they could consider a reoperation starting 6 months or later after the initial procedure.\u003c\/p\u003e\n\n\u003cp\u003eHere's how the procedure itself worked: All participants first underwent diagnostic knee arthroscopy to confirm the meniscus tear. During the same operation, they were then randomly assigned to either APM or placebo surgery using sequentially numbered, opaque, sealed envelopes prepared by a statistician. The randomization was done in a 1:1 ratio with a block size of 4, and patients were stratified according to study site, age group (35–50 or 51–65 years), sex, and whether minor degenerative changes were present on X-ray.\u003c\/p\u003e\n\n\u003cp\u003eFor patients in the \u003cstrong\u003eAPM group\u003c\/strong\u003e, the damaged and loose parts of the meniscus were removed with arthroscopic instruments until solid meniscal tissue was reached, preserving as much of the meniscus as possible. No other surgical procedure was performed.\u003c\/p\u003e\n\n\u003cp\u003eFor patients in the \u003cstrong\u003eplacebo surgery group\u003c\/strong\u003e, the APM was simulated to mimic the sensations and sounds of a true arthroscopic partial meniscectomy. Participants were also kept in the operating room for the same amount of time required to perform an actual APM. The surgical incisions (portal sites) were made so that patients would have identical scars.\u003c\/p\u003e\n\n\u003cp\u003eBoth groups received identical postoperative care, including the same walking aids and the same graduated home-based exercise program.\u003c\/p\u003e\n\n\u003cp\u003eAll participants, all caregivers, and all outcome assessors were kept blinded to the treatment assignment. Participants were followed up with questionnaires at 2, 6, 12, and 24 months after surgery. At the 24-month follow-up, all participants were also clinically examined by an independent orthopedic surgeon who did not know which treatment each patient had received.\u003c\/p\u003e\n\n\u003ch2 id=\"participants\"\u003eWho Participated in the Study\u003c\/h2\u003e\n\n\u003cp\u003eOf the 205 eligible patients, 146 underwent randomization: 70 were assigned to APM and 76 to placebo surgery. The two groups were similar in their baseline characteristics.\u003c\/p\u003e\n\n\u003cp\u003eKey baseline details included:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSex:\u003c\/strong\u003e 28 women (40%) and 42 men (60%) in the APM group; 29 women (38%) and 47 men (62%) in the placebo group\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAverage age:\u003c\/strong\u003e 52.1 years (APM) vs. 52.0 years (placebo)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBody mass index (BMI):\u003c\/strong\u003e 26.9 vs. 27.9 — both in the overweight range\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDuration of symptoms:\u003c\/strong\u003e Median 10 months in both groups\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMechanical symptoms (catching or locking):\u003c\/strong\u003e Reported by 32 (46%) APM patients and 37 (49%) placebo patients\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnstable meniscus tears at arthroscopy:\u003c\/strong\u003e 34 (49%) in the APM group and 41 (54%) in the placebo group\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePositive McMurray test:\u003c\/strong\u003e 16 (23%) vs. 15 (20%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePain provoked by forced flexion:\u003c\/strong\u003e 50 (71%) vs. 59 (78%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePain provoked by joint line palpation:\u003c\/strong\u003e 63 (90%) vs. 74 (97%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePatients in both groups had similar baseline scores on all three primary outcome measures. The average baseline WOMET score was 56.4 (APM) vs. 52.8 (placebo), out of a possible 100. The average Lysholm score was 60.2 vs. 60.1. Pain after exercise was rated at 5.8 vs. 6.1 on a 0–10 scale.\u003c\/p\u003e\n\n\u003cp\u003eTwenty-four eligible patients declined to participate in the trial. These patients were similar to those who were randomized in terms of age, sex, and BMI, and all of them went on to have arthroscopic partial meniscectomy. At the 24-month follow-up, two participants from the placebo-surgery group were lost to follow-up — one who stopped responding to contact attempts and one who died.\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: Results After 24 Months\u003c\/h2\u003e\n\n\u003cp\u003eBoth groups showed marked improvement in all three primary outcome measures over the 24-month follow-up period. However, the difference between the two groups did not reach statistical significance for any outcome — meaning the real surgery was no better than the sham surgery.\u003c\/p\u003e\n\n\u003cp\u003eHere are the detailed results. The researchers measured the change from baseline to 24 months in each of three outcomes:\u003c\/p\u003e\n\n\u003ch3\u003ePrimary Outcomes (Intention-to-Treat Analysis)\u003c\/h3\u003e\n\n\u003cp\u003e\u003cstrong\u003eWOMET score\u003c\/strong\u003e (Western Ontario Meniscal Evaluation Tool — a meniscus-specific quality-of-life questionnaire with 16 items covering three areas: physical symptoms, sports\/recreation\/work\/lifestyle disabilities, and emotions; scores range from 0 to 100, with 100 being the best possible score):\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eImprovement in APM group: 27.3 points (95% CI: 22.1 to 32.4)\u003c\/li\u003e\n  \u003cli\u003eImprovement in placebo group: 31.6 points (95% CI: 26.9 to 36.3)\u003c\/li\u003e\n  \u003cli\u003eBetween-group difference: −4.3 points (95% CI: −11.3 to 2.6) — not statistically significant\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLysholm knee score\u003c\/strong\u003e (an eight-item questionnaire measuring knee function and symptoms in daily activities; scores range from 0 to 100, with higher scores meaning less severe symptoms):\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eImprovement in APM group: 23.1 points (95% CI: 18.8 to 27.4)\u003c\/li\u003e\n  \u003cli\u003eImprovement in placebo group: 26.3 points (95% CI: 22.6 to 30.0)\u003c\/li\u003e\n  \u003cli\u003eBetween-group difference: −3.2 points (95% CI: −8.9 to 2.4) — not statistically significant\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePain after exercise\u003c\/strong\u003e (measured on a 0–10 numerical rating scale, with 0 meaning no pain and 10 meaning extreme pain):\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eImprovement in APM group: 3.5 points (95% CI: 2.8 to 4.2)\u003c\/li\u003e\n  \u003cli\u003eImprovement in placebo group: 3.9 points (95% CI: 3.3 to 4.6)\u003c\/li\u003e\n  \u003cli\u003eBetween-group difference: −0.4 points (95% CI: −1.3 to 0.5) — not statistically significant\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eWhen the results were adjusted for baseline score, study site, age, sex, and the presence or absence of minor degenerative changes on X-ray, the findings were essentially the same — with the adjusted between-group differences being −5.2 for WOMET, −4.3 for Lysholm, and −0.4 for pain after exercise. None reached statistical significance, and the 95% confidence intervals excluded clinically relevant effects in all three primary outcomes.\u003c\/p\u003e\n\n\u003cp\u003eIn other words, the study was designed to detect a minimal clinically important improvement of at least 15.5 points on the WOMET score, 11.5 points on the Lysholm score, and 2.0 points on the pain scale. The observed differences between groups were far smaller than these thresholds, meaning even if there were a slight statistical advantage, it would be too small to matter to patients.\u003c\/p\u003e\n\n\u003ch3\u003eSecondary Outcomes\u003c\/h3\u003e\n\n\u003cp\u003eThe researchers also tracked a range of secondary outcomes at 24 months:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTreatment-group unblinding:\u003c\/strong\u003e 5 patients (7.1%) in the APM group and 7 (9.2%) in the placebo group had symptoms severe enough that their treatment assignment was revealed (p=0.767)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSatisfied patients:\u003c\/strong\u003e 54 (77.1%) in the APM group vs. 58 (78.4%) in the placebo group (p=1.000)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eImproved patients:\u003c\/strong\u003e 61 (87.1%) vs. 63 (85.1%) (p=0.812)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eReoperations:\u003c\/strong\u003e 4 (5.7%) vs. 7 (9.2%) (p=0.537)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFollow-up arthroscopy:\u003c\/strong\u003e 2 (2.9%) in the APM group vs. 6 (7.9%) in the placebo group (p=0.279)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigh tibial osteotomy or total knee replacement:\u003c\/strong\u003e 2 (2.9%) vs. 1 (1.3%) (p=0.607)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eReturn to normal activities:\u003c\/strong\u003e 50 (72.5%) vs. 58 (78.4%) (p=0.442)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSerious adverse events:\u003c\/strong\u003e 1 (1.4%) in the APM group vs. 0 in the placebo group (p=0.479) — the one event was a knee infection that occurred 4 months after the initial operation\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMechanical symptoms at follow-up:\u003c\/strong\u003e 18 (25.7%) vs. 15 (20.3%) (p=0.552)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eStandardized clinical examination of the knee at 24 months — including meniscal tests such as the McMurray test, joint line tenderness, and pain with forced flexion — also showed no statistically significant difference between the two groups.\u003c\/p\u003e\n\n\u003cp\u003eInterestingly, there was a notable finding regarding the 24 patients who declined to participate in the trial and instead went directly to APM. Follow-up data were available for 17 of these patients (5 were lost to follow-up). Their change in WOMET score was significantly greater (43.2 points, SD 22.4) compared with the randomized patients (29.5 points, SD 21.1), with a between-group difference of −13.7 points (95% CI: −25.6 to −2.9). This suggests those who chose surgery may have had different expectations or characteristics that influenced their outcomes.\u003c\/p\u003e\n\n\u003ch2 id=\"subgroup-analysis\"\u003eSubgroup Analysis: Do Certain Patients Benefit More?\u003c\/h2\u003e\n\n\u003cp\u003eA key question for doctors and patients alike is whether specific types of patients might still benefit from APM, even if the average patient doesn't. This study specifically examined two commonly cited subgroups:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients with mechanical symptoms\u003c\/strong\u003e (catching, locking, or clicking sensations in the knee, as assessed by the locking domain question of the Lysholm score)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients with unstable meniscus tears\u003c\/strong\u003e (defined as tears with longitudinal patterns, bucket handle tears, or flap tears — as opposed to stable tears like radial, horizontal, or complex patterns)\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe results were clear: \u003cstrong\u003eno statistically significant difference was found between the APM and placebo groups in any of the primary or secondary outcomes within either subgroup.\u003c\/strong\u003e The p values for interaction were calculated for both subgroup analyses, and no subgroup showed a benefit from real surgery over placebo. This directly contradicts the prevailing belief that patients with mechanical symptoms or unstable tears are more likely to benefit from APM.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe findings of this study carry important messages for patients suffering from degenerative meniscus tears:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFirst, surgery is not automatically better than no surgery.\u003c\/strong\u003e Over 24 months, patients who received simulated surgery improved just as much as those who had the actual meniscus trimmed. The improvements seen in both groups were substantial, which suggests that much of the benefit attributed to arthroscopic surgery may actually come from the body's natural healing process, the passage of time, the structured exercise program, and the placebo effect of having a procedure — not from the removal of the torn cartilage itself.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSecond, the common belief that certain \"red flag\" symptoms predict surgical success was not supported.\u003c\/strong\u003e Even patients who experienced mechanical catching or locking, and those found to have unstable tear patterns during arthroscopy, did not fare better with real surgery than with sham surgery. These findings challenge long-standing assumptions in orthopedic practice.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThird, the decision to undergo surgery after failed conservative treatment deserves reconsideration.\u003c\/strong\u003e The researchers note that previous studies supporting surgery after failed conservative treatment were likely affected by lack of blinding — patients who knew they hadn't had surgery may have been more likely to request it and then feel better about it afterward, regardless of the true physical benefit.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFourth, surgery carries real risks.\u003c\/strong\u003e In this study, one patient in the APM group developed a serious knee infection 4 months after surgery. While infections are relatively rare, this study reminds us that no surgery is completely risk-free, and when the benefit over placebo is negligible, even small risks become more significant in the risk-benefit calculation.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What the Study Couldn't Prove\u003c\/h2\u003e\n\n\u003cp\u003eLike all research, this study has limitations that should be considered when interpreting the results:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExclusion of traumatic tears:\u003c\/strong\u003e Patients with a truly \"traumatic\" onset of symptoms (such as falling from a height or slipping on ice) were excluded. Therefore, the results only directly apply to patients with non-traumatic, degenerative meniscus tears. The researchers acknowledge that the concepts of \"degenerative\" vs. \"traumatic\" are somewhat vague, and the line between the two is not always clear.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients with osteoarthritis were not included:\u003c\/strong\u003e Participants had no or only minimal radiographic osteoarthritis (Kellgren-Lawrence grade 0 or 1). The results may not apply to patients with more advanced arthritis in the knee.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSample size for subgroups:\u003c\/strong\u003e The subgroup analyses (mechanical symptoms and unstable tears) were pre-specified, but the study was not specifically powered to detect small differences within these subgroups. It is possible that a very small benefit exists that the study was not large enough to detect.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBlinding limitations:\u003c\/strong\u003e While the study was carefully blinded, some patients may have been able to guess their treatment group based on subtle differences in the postoperative experience, although the similar rates of unblinding (7.1% vs. 9.2%) suggest this was not a major issue.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLoss to follow-up:\u003c\/strong\u003e Two patients in the placebo group were lost to follow-up (one could not be contacted and one died), which is a very small attrition rate and unlikely to meaningfully affect the results.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations: What Patients Should Consider\u003c\/h2\u003e\n\n\u003cp\u003eBased on this study and the broader body of evidence, here are actionable points that patients with degenerative meniscus tears — and the doctors who treat them — should consider:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTry conservative treatment first.\u003c\/strong\u003e Physical therapy, a graduated home exercise program, activity modification, and pain management should be the first line of treatment for degenerative meniscus tears without osteoarthritis. In this study, patients in both groups received the same structured exercise program, and both improved significantly.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eQuestion the assumption that surgery is needed after failed conservative treatment.\u003c\/strong\u003e This study was specifically designed to test that question (by allowing patients to consider reoperation after 6 months) and found no benefit of real surgery over placebo, even among patients with mechanical symptoms or unstable tears.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBe aware of the placebo effect in surgery.\u003c\/strong\u003e The simulated surgery in this trial produced the same improvements as the real operation. This strongly suggests that expectation, natural healing, and the structured rehabilitation program — not the surgical removal of tissue — are what drive improvement for most patients.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHave an open discussion with your doctor about the evidence.\u003c\/strong\u003e Ask about the results of randomized trials and the difference between what your doctor has observed in practice and what controlled research demonstrates.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider that \"degenerative\" tears are part of aging.\u003c\/strong\u003e Many middle-aged and older adults have meniscus tears on MRI even without symptoms. A tear detected on an MRI does not necessarily mean surgery is required.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you do choose surgery, know the risks.\u003c\/strong\u003e This study recorded one serious complication (knee infection) in 70 surgical patients (1.4%). Discuss the specific risks and benefits with your surgeon before making a decision.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eDr. Raine Sihvonen and colleagues concluded their study with a strong statement: \"In this 2-year follow-up of patients without knee osteoarthritis but with symptoms of a degenerative medial meniscus tear, the outcomes after APM were no better than those after placebo surgery. No evidence could be found to support the prevailing ideas that patients with presence of mechanical symptoms or certain meniscus tear characteristics or those who have failed initial conservative treatment are more likely to benefit from APM.\"\u003c\/p\u003e\n\n\u003cp\u003eThe FIDELITY trial continues to follow participants, and results from the 5-year follow-up are expected to provide even longer-term information about the comparative effectiveness of these two approaches.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWho was eligible for this 2-year meniscus surgery study?\u003c\/h3\u003e\n\u003cp\u003eEligible adults were 35 to 65 years old, had knee symptoms for more than 3 months from a degenerative medial meniscus tear, and had no or only minor arthritis on X-ray. People with tears from obvious trauma, such as a fall or slip on ice, or with a recent locked knee were excluded. The tear was confirmed by MRI and during arthroscopy.\u003c\/p\u003e\n\u003ch3\u003eWhat exactly happened in the placebo surgery group?\u003c\/h3\u003e\n\u003cp\u003ePatients in the placebo group had a simulated arthroscopic partial meniscectomy. The surgeon made small incisions so scars looked identical, and the operation time matched a real procedure, but no meniscal tissue was removed. All patients, caregivers, and outcome assessors were blinded, meaning no one knew which treatment each patient received until the study ended.\u003c\/p\u003e\n\u003ch3\u003eWhat were the main results after 24 months?\u003c\/h3\u003e\n\u003cp\u003eBoth the real surgery and sham surgery groups improved substantially in knee function, pain, and quality-of-life scores at 2 years. However, there was no statistically significant difference between the groups for any measured outcome. The actual operation was not better than placebo surgery for these patients with degenerative meniscus tears and no significant arthritis.\u003c\/p\u003e\n\u003ch3\u003eDid patients with knee catching or locking do better with real surgery?\u003c\/h3\u003e\n\u003cp\u003eNo. In a subgroup analysis of patients who reported mechanical symptoms such as catching, clicking, or locking, there was no statistically significant benefit from arthroscopic partial meniscectomy over placebo surgery. The same was true for patients found to have unstable meniscus tears during arthroscopy. These findings challenge common assumptions about who should have surgery.\u003c\/p\u003e\n\u003ch3\u003eCould patients who had sham surgery later have a reoperation?\u003c\/h3\u003e\n\u003cp\u003eYes. All participants were told that if they did not get adequate symptom relief, they could consider a reoperation starting six months or later after the initial procedure. At the 24-month follow-up, reoperations occurred in 4 patients (5.7%) in the real surgery group and 7 patients (9.2%) in the placebo group. This difference was not statistically significant.\u003c\/p\u003e\n\u003ch3\u003eWhat should a patient do after failing conservative treatment for a degenerative meniscus tear?\u003c\/h3\u003e\n\u003cp\u003eThis study found that real surgery was no better than sham surgery, even among patients who had failed initial conservative treatment. The authors recommend trying physical therapy, a home exercise program, activity modification, and pain management first. They also suggest having an open discussion with your doctor about the evidence and questioning the assumption that surgery is needed after conservative treatment fails.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion before having arthroscopic surgery for a degenerative meniscus tear?\u003c\/h3\u003e\n\u003cp\u003eIn a randomized placebo-surgery trial, arthroscopic partial meniscectomy provided no advantage over sham surgery after 2 years in patients with degenerative medial meniscus tears and no osteoarthritis. Both groups improved equally, indicating that natural healing, time, and a structured exercise program rather than cartilage removal drive recovery. Even patients with mechanical symptoms or unstable tear patterns did not benefit more from real surgery. Thus, a second opinion is worthwhile before deciding on surgery, to explore whether conservative management may suffice. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article:\u003c\/strong\u003e \"Arthroscopic partial meniscectomy versus placebo surgery for a degenerative meniscus tear: a 2-year follow-up of the randomised controlled trial\"\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Raine Sihvonen, Mika Paavola, Antti Malmivaara, Ari Itälä, Antti Joukainen, Heikki Nurmi, Juha Kalske, Anna Ikonen, Timo Järvelä, Tero A H Järvinen, Kari Kanto, Janne Karhunen, Jani Knifsund, Heikki Kröger, Tommi Kääriäinen, Janne Lehtinen, Jukka Nyrhinen, Juha Paloneva, Outi Päiväniemi, Marko Raivio, Janne Sahlman, Roope Sarvilinna, Sikri Tukiainen, Ville-Valtteri Välimäki, Ville Äärimaa, Pirjo Toivonen, Teppo L N Järvinen, and the FIDELITY (Finnish Degenerative Meniscal Lesion Study) Investigators\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e Annals of Rheumatic Diseases, 2018, Volume 77, pages 188–195\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1136\/annrheumdis-2017-211172\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTrial Registration:\u003c\/strong\u003e ClinicalTrials.gov (NCT00549172)\u003c\/p\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research published in a leading medical journal. The original research was approved by the institutional review board of the Pirkanmaa Hospital District in Finland and was conducted in accordance with the Declaration of Helsinki. All study participants gave written informed consent.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47494447136924,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/pt\/products\/knee-surgery-vs-sham-surgery-for-degenerative-meniscus-tears-a-2-year-study-shows-no-advantage","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}